Simcere Pharmaceutical Group Announces Appointment of Chief Scientific Officer
Dr. Zang Jingwu to lead Simcere's Research & Development Team
NANJING, China, Oct. 15, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the appointment of Dr. Zang Jingwu as Chief Scientific Officer of the Company, effective October 8, 2013.
Dr. Zang received his medical degree from Shanghai JiaoTong University School of Medicine. He earned a PhD from the University of Brussels and was a post-doctoral fellow at Harvard Medical School. Dr. Zang later joined the faculty of Baylor College of Medicine as a professor of Neurology and holds a medical license in the State of Texas in US. In his career in China, Dr. Zang was the founding director of the Institute of Health Sciences and Institute Pasteur Shanghai of the Chinese Academy of Sciences. In 2007, Dr. Zang joined GSK as Senior VP and head of GSK's R&D Centre in China; and in 2012, he held one more position as the global head of Neurosciences Therapy Area in GSK.
Mr. Hongquan Liu, the Chief Executive Officer of Simcere, said, "We are extremely pleased that Jingwu will be joining the Simcere management team to lead our R&D efforts. With his rich industry experience and solid knowledge of new drug development, we are confident that Jingwu will be an important contributor to Simcere as we continue to broaden our pipeline of innovative medicines."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Simcere Pharmaceutical Group
In the United States:
Brunswick Group LLC
SOURCE Simcere Pharmaceutical Group
More by this Source
Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
Nov 22, 2013, 05:00 ET
Simcere Pharmaceutical Group Announces Extraordinary General Meeting of Shareholders
Nov 19, 2013, 12:15 ET
Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
Nov 14, 2013, 05:25 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.